These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 1538635)

  • 21. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma.
    Kim DH; Baek JH; Chae YS; Kim YK; Kim HJ; Park YH; Song HS; Chung JS; Hyun MS; Sohn SK
    Leukemia; 2007 Oct; 21(10):2227-30. PubMed ID: 17554383
    [No Abstract]   [Full Text] [Related]  

  • 22. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.
    Olszewski AJ; Winer ES; Castillo JJ
    Leuk Res; 2014 Aug; 38(8):866-73. PubMed ID: 24837081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decision-analytical modelling in health-care economic evaluations.
    Sun X; Faunce T
    Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methods to window data to differentiate between Markov models.
    Schwier JM; Brooks RR; Griffin C
    IEEE Trans Syst Man Cybern B Cybern; 2011 Jun; 41(3):650-63. PubMed ID: 20923740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains.
    Yahalom J
    J Clin Oncol; 2010 Sep; 28(27):4105-7. PubMed ID: 20713874
    [No Abstract]   [Full Text] [Related]  

  • 26. Partially observable Markov decision processes and performance sensitivity analysis.
    Li Y; Yin B; Xi H
    IEEE Trans Syst Man Cybern B Cybern; 2008 Dec; 38(6):1645-51. PubMed ID: 19022734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Fisher RI
    Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
    [No Abstract]   [Full Text] [Related]  

  • 28. Molecular profiling of lymphoma.
    Akhtar S
    N Engl J Med; 2002 Oct; 347(17):1376-7; author reply 1376-7. PubMed ID: 12397201
    [No Abstract]   [Full Text] [Related]  

  • 29. A framework for evaluating sequential clinical interventions with disease progression.
    Mei J; Liu H; Shen W; Sun W; Hu G; Xie G; Pan Y
    Stud Health Technol Inform; 2013; 192():947. PubMed ID: 23920721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
    de Jonge AV; Roosma TJ; Houtenbos I; Vasmel WL; van de Hem K; de Boer JP; van Maanen T; Lindauer-van der Werf G; Beeker A; Timmers GJ; Schaar CG; Soesan M; Poddighe PJ; de Jong D; Chamuleau ME
    Eur J Cancer; 2016 Mar; 55():140-6. PubMed ID: 26820684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse large B cell lymphoma: how can we cure more patients in 2012?
    Moskowitz C
    Best Pract Res Clin Haematol; 2012 Mar; 25(1):41-7. PubMed ID: 22409822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?
    Ferreri AJ; Dognini GP; Govi S; Crocchiolo R; Bouzani M; Bollinger CR; D'Incan M; Delaporte E; Hamadani M; Jardin F; Martusewicz-Boros M; Montanari M; Szomor A; Zucca E; Cavalli F; Ponzoni M
    J Clin Oncol; 2008 Nov; 26(31):5134-6; author reply 5136-7. PubMed ID: 18838697
    [No Abstract]   [Full Text] [Related]  

  • 33. State-of-the-art therapeutics: diffuse large B-cell lymphoma.
    Coiffier B
    J Clin Oncol; 2005 Sep; 23(26):6387-93. PubMed ID: 16155024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.
    Brauner S; Zhou W; Backlin C; Green TM; Folkersen L; Ivanchenko M; Löfström B; Xu-Monette ZY; Young KH; Møller Pedersen L; Boe Møller M; Sundström C; Enblad G; Baecklund E; Wahren-Herlenius M
    J Intern Med; 2015 Sep; 278(3):323-32. PubMed ID: 25880119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The half-cycle correction: banish rather than explain it.
    Barendregt JJ
    Med Decis Making; 2009; 29(4):500-2. PubMed ID: 19571330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
    Frick M; Dörken B; Lenz G
    Best Pract Res Clin Haematol; 2012 Mar; 25(1):3-12. PubMed ID: 22409819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma.
    Dunleavy K; Wilson WH
    J Clin Oncol; 2010 Jun; 28(16):e260; author reply e261-2. PubMed ID: 20421532
    [No Abstract]   [Full Text] [Related]  

  • 39. Decision Tool--a graphical user interface for generic Markov models.
    Kan BD; Levy HL; Wong JB; Pauker SG
    Proc Annu Symp Comput Appl Med Care; 1994; ():1054. PubMed ID: 7949892
    [No Abstract]   [Full Text] [Related]  

  • 40. Advanced DLBCL: as systemic therapy improves, the need for RT diminishes.
    Canellos GP
    Oncology (Williston Park); 2014 Dec; 28(12):1085-6. PubMed ID: 25510807
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.